Arno Therapeutics 10-Q 14 Aug 15 2015 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Aug. 11, 2015
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q2
Entity Registrant Name	Arno Therapeutics, Inc
Entity Central Index Key	1,195,116
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	ARNI
Entity Common Stock, Shares Outstanding		20,408,616

CONDENSED BALANCE SHEETS

CONDENSED BALANCE SHEETS - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Current assets
Cash and cash equivalents	$ 2,368,114	$ 7,948,436
Prepaid expenses and other current assets	170,338	258,046
Total current assets	2,538,452	8,206,482
Property and equipment, net	26,714	30,730
Security deposit	10,455	10,455
Total assets	2,575,621	8,247,667
Current liabilities
Accounts payable	1,089,013	742,448
Accrued expenses and other current liabilities	1,291,099	1,410,293
Capital lease obligation- short term	3,577	3,322
Deferred rent	868	1,048
Total current liabilities	2,384,557	2,157,111
Capital lease obligation- long term	6,068	7,923
Derivative liabilities	5,684,594	6,671,524
Total liabilities	$ 8,075,219	$ 8,836,558
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' DEFICIT
Preferred stock, $0.0001 par value, 35,000,000 shares authorized, none issued and outstanding	$ 0	$ 0
Common stock, $0.0001 par value, 500,000,000 shares authorized, 20,408,616 shares issued and outstanding at June 30, 2015 and December 31, 2014, respectively	5,469	5,469
Additional paid-in capital	83,115,589	81,192,630
Accumulated deficit	(88,620,656)	(81,786,990)
Total stockholders' deficit	(5,499,598)	(588,891)
Total liabilities and stockholders' deficit	$ 2,575,621	$ 8,247,667

CONDENSED BALANCE SHEETS (Paren

CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2015	Dec. 31, 2014
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	35,000,000	35,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	20,408,616	20,408,616
Common stock, shares outstanding	20,408,616	20,408,616

CONDENSED STATEMENTS OF OPERATI

CONDENSED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Operating expenses:
Research and development	$ 2,647,781	$ 4,083,398	$ 5,122,650	$ 8,518,114
General and administrative	1,331,219	1,680,105	2,718,834	3,409,157
Total operating expenses	3,979,000	5,763,503	7,841,484	11,927,271
Loss from operations	(3,979,000)	(5,763,503)	(7,841,484)	(11,927,271)
Other income/(expense):
Interest income	2,573	13,344	7,095	24,860
Interest expense	(380)	0	(790)	0
Other income	531,932	9,244,792	1,001,513	14,950,603
Total other income/(expense)	534,125	9,258,136	1,007,818	14,975,463
Net income/(loss)	$ (3,444,875)	$ 3,494,633	$ (6,833,666)	$ 3,048,192
Net income/(loss) per share - basic	$ (0.17)	$ 0.17	$ (0.33)	$ 0.15
Weighted-average shares outstanding- basic	20,408,616	20,370,331	20,408,616	20,370,331
Net income/(loss) per share - diluted	$ (0.17)	$ 0.14	$ (0.33)	$ 0.12
Weighted-average shares outstanding- diluted	20,408,616	24,802,522	20,408,616	24,804,963

CONDENSED STATEMENT OF STOCKHOL

CONDENSED STATEMENT OF STOCKHOLDERS' DEFICIT - 6 months ended Jun. 30, 2015 - USD ($)	Total	PREFERRED STOCK	COMMON STOCK	ADDITIONAL PAID-IN CAPITAL	ACCUMULATED DEFICIT
Balance at Dec. 31, 2014	$ (588,891)	$ 0	$ 5,469	$ 81,192,630	$ (81,786,990)
Balance (in shares) at Dec. 31, 2014		0	20,408,616
Net loss	(6,833,666)	$ 0	$ 0	0	(6,833,666)
Stock based compensation for services	1,922,959	0	0	1,922,959	0
Balance at Jun. 30, 2015	$ (5,499,598)	$ 0	$ 5,469	$ 83,115,589	$ (88,620,656)
Balance (in shares) at Jun. 30, 2015		0	20,408,616

CONDENSED STATEMENTS OF CASH FL

CONDENSED STATEMENTS OF CASH FLOWS - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Cash flows from operating activities:
Net income/(loss)	$ (6,833,666)	$ 3,048,192
Adjustment to reconcile net income/(loss) to net cash and cash equivalents used in operating activities:
Depreciation and amortization	4,016	6,561
Stock-based compensation	1,922,959	2,418,029
Change in fair value of derivative liability	(986,930)	(14,983,480)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	87,708	18,796
Accounts payable	346,565	(1,580,261)
Accrued expenses	(119,194)	192,070
Deferred rent	(180)	(3,374)
Due to related party	0	(26,039)
Net cash used in operating activities	(5,578,722)	(10,909,506)
Cash flows from investing activities:
Purchase of property and equipment	0	(20,097)
Payment of capital lease obligation	(1,600)	0
Net cash used in investing activities	(1,600)	(20,097)
Cash flows from financing activities:
Net cash provided by financing activities	0	0
Net decrease in cash and cash equivalents	(5,580,322)	(10,929,603)
Cash and cash equivalents at beginning of period	7,948,436	26,774,203
Cash and cash equivalents at end of period	2,368,114	15,844,600
Supplemental schedule of cash flows information:
Cash paid for interest	$ 790	$ 0

DESCRIPTION OF BUSINESS

DESCRIPTION OF BUSINESS	6 Months Ended
	Jun. 30, 2015
Business Combination, Description [Abstract]
DESCRIPTION OF BUSINESS	1. DESCRIPTION OF BUSINESS Arno Therapeutics, Inc. (“Arno” or the “Company”) is developing innovative drug candidates intended to treat patients with cancer and other life threatening diseases. The Company was incorporated in Delaware in March 2000, at which time its name was Laurier International, Inc. (“Laurier”). Pursuant to an Agreement and Plan of Merger dated March 6, 2008 (as amended, the “Merger Agreement”), by and among the Company, Arno Therapeutics, Inc., a Delaware corporation formed on August 1, 2005 (“Old Arno”), and Laurier Acquisition, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“Laurier Acquisition”), on June 3, 2008, Laurier Acquisition merged with and into Old Arno, with Old Arno remaining as the surviving corporation and a wholly-owned subsidiary of Laurier. Immediately following this merger, Old Arno merged with and into Laurier and Laurier’s name was changed to Arno Therapeutics, Inc. These two merger transactions are hereinafter collectively referred to as the “Merger.” Immediately following the Merger, the former stockholders of Old Arno collectively held 95

BASIS OF PRESENTATION AND SUMMA

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	2. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The Company has not yet generated any revenue from the sale of products and, through June 30, 2015, its efforts have been principally devoted to developing its licensed technologies and raising capital. The Company has experienced negative cash flows from operating activities since its inception and has an accumulated deficit of approximately $ 88.6 The accompanying unaudited Condensed Financial Statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q adopted under the Securities Exchange Act of 1934, as amended. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of Arno’s management, the accompanying Condensed Financial Statements contain all adjustments (consisting of normal recurring accruals and adjustments) necessary to present fairly the financial position, results of operations and cash flows of the Company at the dates and for the periods indicated. The interim results for the periods ended June 30, 2015 are not necessarily indicative of results for the full 2015 fiscal year or any other future interim periods. These unaudited Condensed Financial Statements have been prepared by management and should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014, as filed with the Securities and Exchange Commission. The preparation of financial statements in conformity with generally accepted accounting principles requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Estimates and assumptions principally relate to services performed by third parties but not yet invoiced, estimates of the fair value and forfeiture rates of stock options issued to employees and consultants, and estimates of the probability in the fair value of derivative liabilities. Actual results could differ from those estimates. Research and Development Research and development costs are charged to expense as incurred. Research and development includes employee costs, fees associated with operational consultants, contract clinical research organizations, contract manufacturing organizations, clinical site fees, contract laboratory research organizations, contract central testing laboratories, licensing activities, and allocated office, insurance, depreciation, and facilities expenses. The Company accrues for costs incurred as the services are being provided by monitoring the status of the study and the invoices received from its external service providers. The Company adjusts its accruals when actual costs become known. Costs related to the acquisition of technology rights for which development work is still in process are charged to operations as incurred and considered a component of research and development expense. Warrant Liability The Company accounts for the warrants issued in connection with the 2013, 2012 and 2010 Purchase Agreements (see Note 7) in accordance with the guidance on Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, which provides that the Company classify the warrant instrument as a liability at its fair value and adjusts the instrument to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized as a component of other income or expense. The fair value of warrants issued by the Company, in connection with private placements of securities, has been estimated using a Monte Carlo simulation model and, in doing so, the Company’s management utilized a third-party valuation report. The Monte Carlo simulation is a generally accepted statistical method used to generate a defined number of stock price paths in order to develop a reasonable estimate of the range of the Company’s future expected stock prices and minimizes standard error. Recent Accounting Pronouncements In August 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-15, “Presentation of Financial Statements-Going Concern (Topic 205-40)”

LIQUIDITY AND CAPITAL RESOURCES

LIQUIDITY AND CAPITAL RESOURCES	6 Months Ended
	Jun. 30, 2015
Working Capital Information [Abstract]
LIQUIDITY AND CAPITAL RESOURCES	3. LIQUIDITY AND CAPITAL RESOURCES Cash resources as of June 30, 2015 were approximately $ 2.4 7.9 The success of the Company depends on its ability to develop new products to the point of regulatory approval and subsequent revenue generation and, accordingly, to raise enough capital to finance these developmental efforts. Management plans to raise additional capital either by selling shares of the Company’s stock or other securities, issuing debt or by licensing one or more of the Company’s products to finance the continued operating and capital requirements of the Company. Amounts raised will be used to further develop the Company’s product candidates, acquire rights to additional product candidates and for other working capital purposes. While the Company will extend its best efforts to raise additional capital to fund all operations through the third quarter of 2015 and beyond, management can provide no assurances that the Company will be successful in raising sufficient funds. In addition, to the extent that the Company raises additional funds by issuing shares of its common stock or other securities convertible or exchangeable for shares of common stock, stockholders will experience dilution, which may be significant. In the event the Company raises additional capital through debt financings, the Company may incur significant interest expense and become subject to covenants in the related transaction documentation that may affect the manner in which the Company conducts its business. To the extent that the Company raises additional funds through collaboration and licensing arrangements, it may be necessary to relinquish some rights to its technologies or product candidates, or grant licenses on terms that may not be favorable to the Company. Any or all of the foregoing may have a material adverse effect on the Company’s business and financial performance. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The Company’s financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The financial statements do not include any adjustments that might result from the inability of the Company to continue as a going concern.

BASIC AND DILUTED INCOME_(LOSS)

BASIC AND DILUTED INCOME/(LOSS) PER SHARE	6 Months Ended
	Jun. 30, 2015
Earnings Per Share, Basic and Diluted [Abstract]
BASIC AND DILUTED INCOME/(LOSS) PER SHARE	4. BASIC AND DILUTED INCOME/(LOSS) PER SHARE Basic net income/(loss) per share is calculated based on the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is calculated based on the weighted-average number of shares of common stock and other dilutive securities outstanding during the period. The potential dilutive shares of common stock resulting from the assumed exercise of stock options and warrants are determined under the treasury stock method. Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Numerator: Net income/(loss) $ (3,444,875) $ 3,494,633 $ (6,833,666) $ 3,048,192 Denominator: Weighted-average shares of common stock outstanding used in the calculation of basic net income/(loss) per share 20,408,616 20,370,331 20,408,616 20,370,331 Effect of dilutive securities: Warrants to purchase common stock - 4,432,191 - 4,434,632 Weighted-average shares of common stock outstanding used in the calculation of diluted net income/(loss) per share 20,408,616 24,802,522 20,408,616 24,804,963 For all periods presented, potentially dilutive securities are excluded from the computation of fully diluted net income/(loss) per share if their effect is anti-dilutive. For the three and six months ended June 30, 2015, the Company has 4,455,231 warrants to purchase common stock that are potentially dilutive securities. The aggregate number of common equivalent shares (related to options and warrants) that have been excluded from the computations of diluted net income/(loss) per common share at June 30, 2015 and 2014 were 31,678,957 51,464,983

INTANGIBLE ASSETS AND INTELLECT

INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY	6 Months Ended
	Jun. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY	5. INTANGIBLE ASSETS AND INTELLECTUAL PROPERTY License Agreements Onapristone License Agreement The Company’s rights to onapristone are governed by a license agreement with Invivis Pharmaceuticals, Inc. (“Invivis”), dated February 13, 2012. Under this agreement, the Company holds an exclusive, royalty-bearing license for the rights to commercialize onapristone for all therapeutic uses. The license agreement provides the Company with worldwide rights to develop and commercialize onapristone with the exception of the commercialization rights in France; provided that the Company has an option to acquire French commercial rights from Invivis upon notice to Invivis together with additional consideration. The onapristone license agreement provides the Company with exclusive, worldwide rights to a United States patent that relates to assays for predictive biomarkers for anti-progestin efficacy. The Company intends to expand its patent portfolio by filing additional patent applications covering the use of onapristone and/or a companion diagnostic product. This patent is scheduled to expire in 2031. The Company made a one-time cash payment of $ 500,000 15.1 150,000 100,000 350,000 70,833 50,000 Under the license agreement with Invivis, the Company also agreed to indemnify and hold Invivis and its affiliates harmless from any and all claims arising out of or in connection with the production, manufacture, sale, use, lease, consumption or advertisement of onapristone, provided, however, that the Company shall have no obligation to indemnify Invivis for claims that (a) any patent rights infringe third party intellectual property, (b) arise out of the gross negligence or willful misconduct of Invivis, or (c) result from a breach of any representation, warranty, or confidentiality obligation of Invivis under the license agreement. The license agreement will terminate upon the later of (i) the last to expire valid claim contained in the patent rights, and (ii) February 13, 2032 90 90 University of Minnesota License In February 2014, the Company entered into an Exclusive Patent License Agreement with the Regents of the University of Minnesota (the “University”), pursuant to which Arno was granted an exclusive, worldwide, royalty-bearing license for the rights to develop and commercialize technology embodied by certain patent applications relating to a gene expression signature derived from archived breast cancer tissue samples. The Company plans to develop and commercialize this technology as part of the onapristone companion diagnostic development program. The license agreement requires the Company to use commercially reasonable efforts to commercialize the licensed technology as soon as practicable, and includes several performance milestones relating to the development and commercialization of the technology to be achieved by specified dates. Under the terms of the agreement, Arno made a small one-time cash payment and reimbursed the University for past patent expenses it has incurred. The agreement also provides for royalties to be paid to the University on net sales of “Licensed Products” (as defined in the agreement) at a rate in the low-single digits, which royalty obligation terminates on a licensed product-by-licensed product and country-by-country basis upon the first date when there is no longer a valid claim under a licensed patent or patent application covering such licensed product in the country where the licensed product is made or sold. The term of the license agreement continues until the last date on which there is any active licensed patent or pending patent application. The University may terminate the agreement earlier upon certain Arno breaches that remain uncured for a period specified in the agreement. The University may also terminate the agreement if Arno voluntarily files for bankruptcy or similar proceeding, or if a petition for an involuntary bankruptcy proceeding is filed and is not released for 60 days. The agreement may be immediately terminated upon notice to Arno if the Company commences or maintains a proceeding in which it asserts that the licensed patents are invalid or unenforceable. Arno may terminate the agreement at any time and for any reason upon 90 days’ written notice. The license agreement further provides that the Company will indemnify and hold the University and its affiliates harmless from any and all suits, actions, claims, liabilities, demands, damages, losses or expenses relating to Arno’s exercise of its rights under the agreement, including the right to commercialize the licensed technology. The University is required to indemnify Arno with respect to claims relating to or resulting from its breach of the agreement. AR-12 and AR-42 License Agreements The Company’s rights to both AR-12 and AR-42 are governed by separate license agreements with The Ohio State University Research Foundation (“Ohio State”) entered into in January 2008. Pursuant to each of these agreements, Ohio State granted the Company exclusive, worldwide, royalty-bearing licenses to commercialize certain patent applications, know-how and improvements relating to AR-12 and AR-42 for all therapeutic uses. In 2008, pursuant to the Company’s license agreements for AR-12 and AR-42, the Company made one-time cash payments to Ohio State in the aggregate amount of $ 450,000 6.1 5.0 5.1 4.0 The license agreements with Ohio State further provide that the Company will indemnify Ohio State from any and all claims arising out of the death of or injury to any person or persons or out of any damage to property, or resulting from the production, manufacture, sale, use, lease, consumption or advertisement of either AR-12 or AR-42, except to the extent that any such claim arises out of the gross negligence or willful misconduct of Ohio State. The license agreements for AR-12 and AR-42 each expire on the later of (i) the expiration of the last valid claim contained in any licensed patent and (ii) 20 90 90

FAIR VALUE OF FINANCIAL INSTRUM

FAIR VALUE OF FINANCIAL INSTRUMENTS	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
FAIR VALUE OF FINANCIAL INSTRUMENTS	6. FAIR VALUE OF FINANCIAL INSTRUMENTS The Company defines fair value as the amount at which an asset (or liability) could be bought (or incurred) or sold (or settled) in a current transaction between willing parties, that is, other than in a forced or liquidation sale. The fair value estimates presented in the table below are based on information available to the Company as of June 30, 2015. The accounting standard regarding fair value measurements discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The standard utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels: • Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. • Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. • Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions. Quoted Market Prices in Active Significant Other Significant Other Fair Value Markets Observable Inputs Unobservable Inputs June 30, 2015 (Level 1) (Level 2) (Level 3) Liabilities: Warrant liability - 2010 Class B $ 802 $ - $ - $ 802 Warrant liability - 2012 Series A 3,002,382 - - 3,002,382 Warrant liability - 2012 placement agent 41,711 - - 41,711 Warrant liability - 2013 Series D 2,625,191 - - 2,625,191 Warrant liability - 2013 placement agent 14,508 - - 14,508 Total $ 5,684,594 $ - $ - $ 5,684,594 Quoted Market Prices in Active Significant Other Significant Other Fair Value Markets Observable Inputs Unobservable Inputs Dec 31, 2014 (Level 1) (Level 2) (Level 3) Liabilities: Warrant liability - 2010 Class B $ 28,066 $ - $ - $ 28,066 Warrant liability - 2012 Series A&B 3,520,319 - - 3,520,319 Warrant liability - 2012 placement agent 67,246 - - 67,246 Warrant liability - 2013 Series D&E 3,036,986 - - 3,036,986 Warrant liability - 2013 placement agent 18,907 - - 18,907 Total $ 6,671,524 $ - $ - $ 6,671,524 Fair Value Measurement Using Significant Unobservable Inputs (Level 3) Total 2013 2012 Warrant 2013 2013 Placement 2012 2012 Placement 2010 Liability Series E Series D Agent Series B Series A Agent Class B Balance at January 1, 2014 $ 35,864,881 $ 5,855,206 $ 12,482,527 $ 98,080 $ 2,816,676 $ 13,887,307 $ 362,633 $ 362,452 Total gains or losses: Unrealized depreciation (29,193,357) (5,829,469) (9,471,278) (79,173) (2,804,295) (10,379,369) (295,387) (334,386) Balance at December 31, 2014 $ 6,671,524 $ 25,737 $ 3,011,249 $ 18,907 $ 12,381 $ 3,507,938 $ 67,246 $ 28,066 Total gains or losses: Unrealized depreciation (986,930) (25,737) (386,058) (4,399) (12,381) (505,556) (25,535) (27,264) Balance at June 30, 2015 $ 5,684,594 $ - $ 2,625,191 $ 14,508 $ - $ 3,002,382 $ 41,711 $ 802 Value per Warrant $ 0.234 $ - $ 0.204 $ 0.221 $ - $ 0.291 $ 0.147 $ 0.001

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	6 Months Ended
	Jun. 30, 2015
Stockholders Equity Note [Abstract]
STOCKHOLDERS' EQUITY	7. STOCKHOLDERS’ EQUITY Common Stock As of June 30, 2015, the Company had 20,408,616 36,134,188 Warrants In accordance with the 2010 sale and issuance of Series A preferred stock, the Company issued two-and-one-half-year “Class A” warrants to purchase an aggregate of 152,740 8.00 801,885 9.20 3.55 0.0 152,740 Pursuant to the 2012 Purchase Agreement for the sale and issuance of 8 6,190,500 4.00 6,190,500 2.40 12 2.40 10,317,464 3.0 3.5 6,190,500 In connection with the sale of the Debentures and 2012 Warrants, the Company engaged Maxim Group LLC, or Maxim, to serve as placement agent. In consideration for its services, the Company paid Maxim a placement fee of $ 1,035,000 7,500 283,750 2.64 0.0 0.1 Under the terms of the 2013 Purchase Agreement for the issuance and sale of common stock, each Purchaser received Series D and Series E Warrants and had the option to elect to receive a Series C Warrant in lieu of a Share in connection with each Unit it purchased. The Series C Warrants have a five-year term and are exercisable at an initial exercise price of $ 0.01 4.00 2.40 2.6 3.0 12,868,585 The 2013 Warrants are required to be exercised for cash, provided that if during the term of the Warrants there is not an effective registration statement under the Securities Act covering the resale of the shares issuable upon exercise of the Warrants, then the Warrants may be exercised on a cashless (net exercise) basis. Weighted Exercise Average Expiration Warrants Grant Date Warrants Issued Price Exercise Date Exercised Outstanding 09/03/2010 801,885 $ 3.55 $ 3.55 09/03/2015 - 801,885 09/03/2010 132,116 $ 8.80 $ 8.80 09/03/2015 - 132,116 11/26/2012 8,822,887 $ 2.40 $ 2.40 11/26/2017 - 8,822,887 11/26/2012 261,250 $ 2.64 $ 2.64 11/26/2017 - 261,250 12/18/2012 1,494,577 $ 2.40 $ 2.40 12/18/2017 - 1,494,577 12/18/2012 22,500 $ 2.64 $ 2.64 12/18/2017 - 22,500 10/29/2013 4,455,231 $ 0.01 $ 0.01 10/29/2018 - 4,455,231 10/29/2013 12,868,585 $ 4.00 $ 4.00 10/29/2018 - 12,868,585 10/29/2013 65,650 $ 2.64 $ 2.64 10/29/2018 - 65,650 28,924,681 $ 2.81 - 28,924,681

STOCK OPTION PLAN

STOCK OPTION PLAN	6 Months Ended
	Jun. 30, 2015
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]
STOCK OPTION PLAN	8. STOCK OPTION PLAN The Company’s 2005 Stock Option Plan (the “Plan”) was originally adopted by the Board of Directors of Old Arno in August 2005, and was assumed by the Company on June 3, 2008 in connection with the Merger. After giving effect to the Merger, there were initially 373,831 875,000 945,276 11,155,295 The Plan is administered by the Board, or a committee appointed by the Board, which determines recipients and types of awards to be granted, including the number of shares subject to the awards, the exercise price and the vesting schedule. The term of stock options granted under the Plan cannot exceed 10 As of June 30, 2015, there are 3,905,808 Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Options granted - - - 2,186,957 The Company estimated the fair value of each option award granted using the Black-Scholes option-pricing model. Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Expected volatility N/A N/A N/A 92% Expected term N/A N/A N/A 6 years Dividend yield N/A N/A N/A 0.0% Risk- free interest rate N/A N/A N/A 1.57% - 1.58% Stock price N/A N/A N/A $2.23 - $2.90 Forfeiture rate N/A N/A N/A 0.0% Weighted- Aggregate Number of Average Intrinsic Shares Exercise Price Value Options outstanding at December 31, 2014 7,339,118 $ 2.59 $ - Granted - - - Exercised - - - Cancelled (129,611) $ 2.75 - Options outstanding at June 30, 2015 7,209,507 $ 2.59 $ - Options vested and expected to vest at June 30, 2015 7,209,507 $ 2.59 $ - Exercisable at June 30, 2015 3,990,184 $ 2.73 $ - Shares available for grant under the 2005 Plan 3,905,808 Outstanding Exercisable Weighted- Average Weighted- Remaining Average Weighted- Number of Contractual Exercise Number of Average Exercise Price Shares Life (Years) Price Shares Exercise Price $ 0.85 136,785 9.35 $ 0.85 26,597 $ 0.85 $ 1.30 100,000 9.27 $ 1.30 - $ 1.30 $ 2.23 223,445 8.65 $ 2.23 83,792 $ 2.23 $ 2.40 5,188,107 7.69 $ 2.40 3,020,588 $ 2.40 $ 2.90 1,458,787 8.36 $ 2.90 756,824 $ 2.90 $ 8.00 65,000 5.07 $ 8.00 65,000 $ 8.00 $ 19.38 37,383 2.78 $ 19.38 37,383 $ 19.38 Total 7,209,507 7.86 $ 2.59 3,990,184 $ 2.73 Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Research and development $ 284,947 $ 300,259 $ 554,750 $ 547,586 General and administrative 672,004 952,714 1,368,209 1,870,443 Total $ 956,951 $ 1,252,973 $ 1,922,959 $ 2,418,029 The fair value of options vested under the Plan was approximately $ 974,425 955,740 2,655,262 1,916,729 At June 30, 2015, total unrecognized estimated compensation cost related to stock options granted prior to that date was approximately $ 5,647,085 2.4 Common stock, stock options or other equity instruments issued to non-employees (including consultants and all members of the Company’s Scientific Advisory Board) as consideration for goods or services received by the Company are accounted for based on the fair value of the equity instruments issued (unless the fair value of the consideration received can be more reliably measured). The fair value of stock options is determined using the Black-Scholes option-pricing model and is expensed as the underlying options vest. The fair value of any options issued to non-employees is recorded as expense over the applicable service periods.

BASIS OF PRESENTATION AND SUM15

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Research and Development	Research and Development Research and development costs are charged to expense as incurred. Research and development includes employee costs, fees associated with operational consultants, contract clinical research organizations, contract manufacturing organizations, clinical site fees, contract laboratory research organizations, contract central testing laboratories, licensing activities, and allocated office, insurance, depreciation, and facilities expenses. The Company accrues for costs incurred as the services are being provided by monitoring the status of the study and the invoices received from its external service providers. The Company adjusts its accruals when actual costs become known. Costs related to the acquisition of technology rights for which development work is still in process are charged to operations as incurred and considered a component of research and development expense.
Warrant Liability	Warrant Liability The Company accounts for the warrants issued in connection with the 2013, 2012 and 2010 Purchase Agreements (see Note 7) in accordance with the guidance on Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity, which provides that the Company classify the warrant instrument as a liability at its fair value and adjusts the instrument to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized as a component of other income or expense. The fair value of warrants issued by the Company, in connection with private placements of securities, has been estimated using a Monte Carlo simulation model and, in doing so, the Company’s management utilized a third-party valuation report. The Monte Carlo simulation is a generally accepted statistical method used to generate a defined number of stock price paths in order to develop a reasonable estimate of the range of the Company’s future expected stock prices and minimizes standard error.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-15, “Presentation of Financial Statements-Going Concern (Topic 205-40)”

BASIC AND DILUTED INCOME_(LOS16

BASIC AND DILUTED INCOME/(LOSS) PER SHARE (Tables)	6 Months Ended
	Jun. 30, 2015
Earnings Per Share, Basic and Diluted [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The following table is a reconciliation of the numerator and denominator used in the calculation of basic and diluted net income/(loss) per share. Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Numerator: Net income/(loss) $ (3,444,875) $ 3,494,633 $ (6,833,666) $ 3,048,192 Denominator: Weighted-average shares of common stock outstanding used in the calculation of basic net income/(loss) per share 20,408,616 20,370,331 20,408,616 20,370,331 Effect of dilutive securities: Warrants to purchase common stock - 4,432,191 - 4,434,632 Weighted-average shares of common stock outstanding used in the calculation of diluted net income/(loss) per share 20,408,616 24,802,522 20,408,616 24,804,963

FAIR VALUE OF FINANCIAL INSTR17

FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value Hierarchy for Liabilities Measured at Fair Value on Recurring Basis	Quoted Market Prices in Active Significant Other Significant Other Fair Value Markets Observable Inputs Unobservable Inputs June 30, 2015 (Level 1) (Level 2) (Level 3) Liabilities: Warrant liability - 2010 Class B $ 802 $ - $ - $ 802 Warrant liability - 2012 Series A 3,002,382 - - 3,002,382 Warrant liability - 2012 placement agent 41,711 - - 41,711 Warrant liability - 2013 Series D 2,625,191 - - 2,625,191 Warrant liability - 2013 placement agent 14,508 - - 14,508 Total $ 5,684,594 $ - $ - $ 5,684,594 Quoted Market Prices in Active Significant Other Significant Other Fair Value Markets Observable Inputs Unobservable Inputs Dec 31, 2014 (Level 1) (Level 2) (Level 3) Liabilities: Warrant liability - 2010 Class B $ 28,066 $ - $ - $ 28,066 Warrant liability - 2012 Series A&B 3,520,319 - - 3,520,319 Warrant liability - 2012 placement agent 67,246 - - 67,246 Warrant liability - 2013 Series D&E 3,036,986 - - 3,036,986 Warrant liability - 2013 placement agent 18,907 - - 18,907 Total $ 6,671,524 $ - $ - $ 6,671,524
Schedule of Derivative Liabilities at Fair Value	The following table provides a summary of changes in fair value of the Company’s liabilities, as well as the portion of losses included in income attributable to unrealized depreciation that relate to those liabilities held at June 30, 2015: Fair Value Measurement Using Significant Unobservable Inputs (Level 3) Total 2013 2012 Warrant 2013 2013 Placement 2012 2012 Placement 2010 Liability Series E Series D Agent Series B Series A Agent Class B Balance at January 1, 2014 $ 35,864,881 $ 5,855,206 $ 12,482,527 $ 98,080 $ 2,816,676 $ 13,887,307 $ 362,633 $ 362,452 Total gains or losses: Unrealized depreciation (29,193,357) (5,829,469) (9,471,278) (79,173) (2,804,295) (10,379,369) (295,387) (334,386) Balance at December 31, 2014 $ 6,671,524 $ 25,737 $ 3,011,249 $ 18,907 $ 12,381 $ 3,507,938 $ 67,246 $ 28,066 Total gains or losses: Unrealized depreciation (986,930) (25,737) (386,058) (4,399) (12,381) (505,556) (25,535) (27,264) Balance at June 30, 2015 $ 5,684,594 $ - $ 2,625,191 $ 14,508 $ - $ 3,002,382 $ 41,711 $ 802 Value per Warrant $ 0.234 $ - $ 0.204 $ 0.221 $ - $ 0.291 $ 0.147 $ 0.001

STOCKHOLDERS' EQUITY (Tables)

STOCKHOLDERS' EQUITY (Tables)	6 Months Ended
	Jun. 30, 2015
Stockholders Equity Note [Abstract]
Summary of All Outstanding Warrants to Purchase Shares of Common Stock	Below is a table that summarizes all outstanding warrants to purchase shares of the Company’s common stock as of June 30, 2015. Weighted Exercise Average Expiration Warrants Grant Date Warrants Issued Price Exercise Date Exercised Outstanding 09/03/2010 801,885 $ 3.55 $ 3.55 09/03/2015 - 801,885 09/03/2010 132,116 $ 8.80 $ 8.80 09/03/2015 - 132,116 11/26/2012 8,822,887 $ 2.40 $ 2.40 11/26/2017 - 8,822,887 11/26/2012 261,250 $ 2.64 $ 2.64 11/26/2017 - 261,250 12/18/2012 1,494,577 $ 2.40 $ 2.40 12/18/2017 - 1,494,577 12/18/2012 22,500 $ 2.64 $ 2.64 12/18/2017 - 22,500 10/29/2013 4,455,231 $ 0.01 $ 0.01 10/29/2018 - 4,455,231 10/29/2013 12,868,585 $ 4.00 $ 4.00 10/29/2018 - 12,868,585 10/29/2013 65,650 $ 2.64 $ 2.64 10/29/2018 - 65,650 28,924,681 $ 2.81 - 28,924,681

STOCK OPTION PLAN (Tables)

STOCK OPTION PLAN (Tables)	6 Months Ended
	Jun. 30, 2015
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]
Schedule of Share-based Compensation, Activity	The Company issued the following stock options during the three and six month periods ended June 30, 2015 and 2014, respectively: Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Options granted - - - 2,186,957
Assumptions Used in Estimating Fair Value of Each Option Award Granted Using Black-Scholes Option-Pricing Model	The following assumptions were used for the six months ended June 30, 2014 as no options were granted in 2015 and the three months ended June 30, 2014: Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Expected volatility N/A N/A N/A 92% Expected term N/A N/A N/A 6 years Dividend yield N/A N/A N/A 0.0% Risk- free interest rate N/A N/A N/A 1.57% - 1.58% Stock price N/A N/A N/A $2.23 - $2.90 Forfeiture rate N/A N/A N/A 0.0%
Summary of Status of Options Issued And Changes in Options Outstanding	A summary of the status of the options issued under the Plan at June 30, 2015, and information with respect to the changes in options outstanding, is as follows: Weighted- Aggregate Number of Average Intrinsic Shares Exercise Price Value Options outstanding at December 31, 2014 7,339,118 $ 2.59 $ - Granted - - - Exercised - - - Cancelled (129,611) $ 2.75 - Options outstanding at June 30, 2015 7,209,507 $ 2.59 $ - Options vested and expected to vest at June 30, 2015 7,209,507 $ 2.59 $ - Exercisable at June 30, 2015 3,990,184 $ 2.73 $ - Shares available for grant under the 2005 Plan 3,905,808
Summary of Stock Options Outstanding	The following table summarizes information about stock options outstanding at June 30, 2015: Outstanding Exercisable Weighted- Average Weighted- Remaining Average Weighted- Number of Contractual Exercise Number of Average Exercise Price Shares Life (Years) Price Shares Exercise Price $ 0.85 136,785 9.35 $ 0.85 26,597 $ 0.85 $ 1.30 100,000 9.27 $ 1.30 - $ 1.30 $ 2.23 223,445 8.65 $ 2.23 83,792 $ 2.23 $ 2.40 5,188,107 7.69 $ 2.40 3,020,588 $ 2.40 $ 2.90 1,458,787 8.36 $ 2.90 756,824 $ 2.90 $ 8.00 65,000 5.07 $ 8.00 65,000 $ 8.00 $ 19.38 37,383 2.78 $ 19.38 37,383 $ 19.38 Total 7,209,507 7.86 $ 2.59 3,990,184 $ 2.73
Stock-Based Compensation Costs	Stock-based compensation costs under the Plan for the three and six month periods ended June 30, 2015 and 2014 are as follows: Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Research and development $ 284,947 $ 300,259 $ 554,750 $ 547,586 General and administrative 672,004 952,714 1,368,209 1,870,443 Total $ 956,951 $ 1,252,973 $ 1,922,959 $ 2,418,029

Description of Business - Addit

Description of Business - Additional Information (Detail)	Jun. 30, 2015
Organization and Nature of Operations [Line Items]
Percentage of outstanding common stock collectively held by former stockholders of Old Arno	95.00%

Basis of Presentation And Sum21

Basis of Presentation And Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Summary Of Significant Accounting Policies [Line Items]
Accumulated deficit	$ (88,620,656)	$ (81,786,990)

Liquidity and Capital Resourc22

Liquidity and Capital Resources - Additional Information (Detail) - USD ($)	Jun. 30, 2015	Dec. 31, 2014	Jun. 30, 2014	Dec. 31, 2013
Working Capital Detail [Line Items]
Cash and cash equivalents	$ 2,368,114	$ 7,948,436	$ 15,844,600	$ 26,774,203

Basic And Diluted Income_(Los23

Basic And Diluted Income/(Loss) Per Share - Additional Information (Detail) - shares	3 Months Ended	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2015	Jun. 30, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Warrants to purchase of common stock	4,455,231	4,455,231
Options Warrants Convertible Debentures
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount		31,678,957	51,464,983

Basic and diluted net income_(l

Basic and diluted net income/(loss) per share (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Numerator:
Net income/(loss)	$ (3,444,875)	$ 3,494,633	$ (6,833,666)	$ 3,048,192
Denominator:
Weighted-average shares of common stock outstanding used in the calculation of basic net income/(loss) per share	20,408,616	20,370,331	20,408,616	20,370,331
Effect of dilutive securities:
Warrants to purchase common stock	0	4,432,191	0	4,434,632
Weighted-average shares of common stock outstanding used in the calculation of diluted net income/(loss) per share	20,408,616	24,802,522	20,408,616	24,804,963

Intangible Assets and Intelle25

Intangible Assets and Intellectual Property - Additional Information (Detail) - USD ($)	Feb. 13, 2012	Mar. 31, 2014	Jan. 31, 2014	Oct. 31, 2013	Jun. 30, 2015	Dec. 31, 2008
Finite-Lived Intangible Assets [Line Items]
Services agreement monthly payment	$ 70,833	$ 50,000
Onapristone License Agreement
Finite-Lived Intangible Assets [Line Items]
Written notice period for termination of license agreement if breach is not cured	90 days
Onapristone License Agreement | Invivis Pharmaceuticals, Inc
Finite-Lived Intangible Assets [Line Items]
Cash paid under license agreement	$ 500,000		$ 100,000	$ 150,000
Aggregate potential milestone payments	$ 15,100,000
License agreement termination date	Feb. 13, 2032
Prior written notice period for termination of license agreement by the company for any reason	90 days
Onapristone License Agreement | Invivis Pharmaceuticals, Inc | Next Milestone Payment
Finite-Lived Intangible Assets [Line Items]
Cash paid under license agreement					$ 350,000
AR-12 and AR-42 License Agreements | Ohio State University Research Foundation
Finite-Lived Intangible Assets [Line Items]
Cash paid under license agreement						$ 450,000
Written notice period for termination of license agreement if breach is not cured						90 days
Prior written notice period for termination of license agreement by the company for any reason						90 days
License agreement expiration date						20 years
AR-12 License Agreement | Ohio State University Research Foundation
Finite-Lived Intangible Assets [Line Items]
Aggregate potential milestone payments						$ 6,100,000
Potential milestone payments, due after market approval						5,000,000
AR-42 License Agreement | Ohio State University Research Foundation
Finite-Lived Intangible Assets [Line Items]
Aggregate potential milestone payments						5,100,000
Potential milestone payments, due after market approval						$ 4,000,000

Fair Value Hierarchy for Liabil

Fair Value Hierarchy for Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Liabilities
Derivative Liabilities Noncurrent	$ 5,684,594	$ 6,671,524
Fair Value, Measurements, Recurring
Liabilities
Derivative Liabilities Noncurrent	5,684,594	6,671,524
Fair Value, Measurements, Recurring | Warrant liability - 2010 Class B
Liabilities
Derivative Liabilities Noncurrent	802	28,066
Fair Value, Measurements, Recurring | Warrant liability - 2012 Series A
Liabilities
Derivative Liabilities Noncurrent	3,002,382	3,520,319
Fair Value, Measurements, Recurring | Warrant liability - 2012 placement agent
Liabilities
Derivative Liabilities Noncurrent	41,711	67,246
Fair Value, Measurements, Recurring | Warrant liability - 2013 Series D
Liabilities
Derivative Liabilities Noncurrent	2,625,191	3,036,986
Fair Value, Measurements, Recurring | Warrant liability - 2013 placement agent
Liabilities
Derivative Liabilities Noncurrent	14,508	18,907
Quoted Market Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring
Liabilities
Derivative Liabilities Noncurrent	0	0
Quoted Market Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Warrant liability - 2010 Class B
Liabilities
Derivative Liabilities Noncurrent	0	0
Quoted Market Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Warrant liability - 2012 Series A
Liabilities
Derivative Liabilities Noncurrent	0	0
Quoted Market Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Warrant liability - 2012 placement agent
Liabilities
Derivative Liabilities Noncurrent	0	0
Quoted Market Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Warrant liability - 2013 Series D
Liabilities
Derivative Liabilities Noncurrent	0	0
Quoted Market Prices in Active Markets (Level 1) | Fair Value, Measurements, Recurring | Warrant liability - 2013 placement agent
Liabilities
Derivative Liabilities Noncurrent	0	0
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring
Liabilities
Derivative Liabilities Noncurrent	0	0
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Warrant liability - 2010 Class B
Liabilities
Derivative Liabilities Noncurrent	0	0
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Warrant liability - 2012 Series A
Liabilities
Derivative Liabilities Noncurrent	0	0
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Warrant liability - 2012 placement agent
Liabilities
Derivative Liabilities Noncurrent	0	0
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Warrant liability - 2013 Series D
Liabilities
Derivative Liabilities Noncurrent	0	0
Significant Other Observable Inputs (Level 2) | Fair Value, Measurements, Recurring | Warrant liability - 2013 placement agent
Liabilities
Derivative Liabilities Noncurrent	0	0
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring
Liabilities
Derivative Liabilities Noncurrent	5,684,594	6,671,524
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Warrant liability - 2010 Class B
Liabilities
Derivative Liabilities Noncurrent	802	28,066
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Warrant liability - 2012 Series A
Liabilities
Derivative Liabilities Noncurrent	3,002,382	3,520,319
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Warrant liability - 2012 placement agent
Liabilities
Derivative Liabilities Noncurrent	41,711	67,246
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Warrant liability - 2013 Series D
Liabilities
Derivative Liabilities Noncurrent	2,625,191	3,036,986
Significant Unobservable Inputs (Level 3) | Fair Value, Measurements, Recurring | Warrant liability - 2013 placement agent
Liabilities
Derivative Liabilities Noncurrent	$ 14,508	$ 18,907

Summary of Changes in Fair Valu

Summary of Changes in Fair Value of Liabilities (Detail) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
2013 Series E
Warrant Liability
Balance	$ 25,737	$ 5,855,206
Total gains or losses:
Unrealized depreciation	(25,737)	(5,829,469)
Balance	$ 0	25,737
Value per Warrant	$ 0
2013 Series D
Warrant Liability
Balance	$ 3,011,249	12,482,527
Total gains or losses:
Unrealized depreciation	(386,058)	(9,471,278)
Balance	$ 2,625,191	3,011,249
Value per Warrant	$ 0.204
2013 Placement Agent
Warrant Liability
Balance	$ 18,907	98,080
Total gains or losses:
Unrealized depreciation	(4,399)	(79,173)
Balance	$ 14,508	18,907
Value per Warrant	$ 0.221
2012 Series B
Warrant Liability
Balance	$ 12,381	2,816,676
Total gains or losses:
Unrealized depreciation	(12,381)	(2,804,295)
Balance	$ 0	12,381
Value per Warrant	$ 0
2012 Series A
Warrant Liability
Balance	$ 3,507,938	13,887,307
Total gains or losses:
Unrealized depreciation	(505,556)	(10,379,369)
Balance	$ 3,002,382	3,507,938
Value per Warrant	$ 0.291
2012 Placement Agent
Warrant Liability
Balance	$ 67,246	362,633
Total gains or losses:
Unrealized depreciation	(25,535)	(295,387)
Balance	$ 41,711	67,246
Value per Warrant	$ 0.147
2010 Class B
Warrant Liability
Balance	$ 28,066	362,452
Total gains or losses:
Unrealized depreciation	(27,264)	(334,386)
Balance	$ 802	28,066
Value per Warrant	$ 0.001
Warrant
Warrant Liability
Balance	$ 6,671,524	35,864,881
Total gains or losses:
Unrealized depreciation	(986,930)	(29,193,357)
Balance	$ 5,684,594	$ 6,671,524
Value per Warrant	$ 0.234

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	1 Months Ended	6 Months Ended	12 Months Ended
	Jan. 31, 2015	Jun. 30, 2015	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2014	Dec. 31, 2010
Stockholders Equity Note [Line Items]
Common stock, shares issued		20,408,616			20,408,616
Derivative liabilities		$ 5,684,594			$ 6,671,524
Potential Additional Equity Financing				$ 12,000,000
Securities Purchase Agreement | Private Placement
Stockholders Equity Note [Line Items]
Debt Instrument, Interest Rate, Stated Percentage				8.00%
Common Shares
Stockholders Equity Note [Line Items]
Shares Of Common Stock Reserved For Issuance Upon The Exercise Of Outstanding Options And Warrants		36,134,188
Maxim Group Llc
Stockholders Equity Note [Line Items]
Common stock, shares issued				7,500
Number of securities called by warrants				283,750
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 2.64
Derivative liabilities		$ 0			100,000
Placement Fee Paid				$ 1,035,000
Class A Warrants
Stockholders Equity Note [Line Items]
Number of securities called by warrants						152,740
Class Of Warrant Or Right Initial Exercise Price Of Warrants Or Rights						$ 8
Number Of Warrants Expired Unexercised			152,740
Class B Warrants
Stockholders Equity Note [Line Items]
Number of securities called by warrants						801,885
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 3.55
Class Of Warrant Or Right Initial Exercise Price Of Warrants Or Rights						$ 9.20
Series A Warrant
Stockholders Equity Note [Line Items]
Number of securities called by warrants			10,317,464	6,190,500
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 2.40	$ 4
Series B Warrant
Stockholders Equity Note [Line Items]
Number of securities called by warrants				6,190,500
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 2.40
Number Of Warrants Expired Unexercised	6,190,500
Series D Warrant
Stockholders Equity Note [Line Items]
Number of securities called by warrants			12,868,585
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 4
Series E Warrant
Stockholders Equity Note [Line Items]
Number of securities called by warrants			12,868,585
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 2.40
Number Of Warrants Expired Unexercised	12,868,585
Class A and B Warrants
Stockholders Equity Note [Line Items]
Derivative liabilities		0
Series D and E Warrants
Stockholders Equity Note [Line Items]
Derivative liabilities		2,600,000			3,000,000
Securities Purchase and Registration Rights Agreement | Series C Warrant
Stockholders Equity Note [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.01
Series A and B Warrants
Stockholders Equity Note [Line Items]
Derivative liabilities		$ 3,000,000			$ 3,500,000

Summary of All Outstanding Warr

Summary of All Outstanding Warrants to Purchase Shares of Common Stock (Detail) - Jun. 30, 2015	$ / shares$ / Warrantshares
Warrant 1
Class of Warrant or Right [Line Items]
Grant Date	Sep. 3, 2010
Warrants Issued	801,885
Exercise Price | $ / shares	$ 3.55
Weighted Average Exercise Price | $ / Warrant	3.55
Expiration Date	Sep. 3, 2015
Exercised	0
Warrants Outstanding	801,885
Warrant 2
Class of Warrant or Right [Line Items]
Grant Date	Sep. 3, 2010
Warrants Issued	132,116
Exercise Price | $ / shares	$ 8.80
Weighted Average Exercise Price | $ / Warrant	8.80
Expiration Date	Sep. 3, 2015
Exercised	0
Warrants Outstanding	132,116
Warrant 3
Class of Warrant or Right [Line Items]
Grant Date	Nov. 26, 2012
Warrants Issued	8,822,887
Exercise Price | $ / shares	$ 2.40
Weighted Average Exercise Price | $ / Warrant	2.40
Expiration Date	Nov. 26, 2017
Exercised	0
Warrants Outstanding	8,822,887
Warrant 4
Class of Warrant or Right [Line Items]
Grant Date	Nov. 26, 2012
Warrants Issued	261,250
Exercise Price | $ / shares	$ 2.64
Weighted Average Exercise Price | $ / Warrant	2.64
Expiration Date	Nov. 26, 2017
Exercised	0
Warrants Outstanding	261,250
Warrant 5
Class of Warrant or Right [Line Items]
Grant Date	Dec. 18, 2012
Warrants Issued	1,494,577
Exercise Price | $ / shares	$ 2.40
Weighted Average Exercise Price | $ / Warrant	2.40
Expiration Date	Dec. 18, 2017
Exercised	0
Warrants Outstanding	1,494,577
Warrant 6
Class of Warrant or Right [Line Items]
Grant Date	Dec. 18, 2012
Warrants Issued	22,500
Exercise Price | $ / shares	$ 2.64
Weighted Average Exercise Price | $ / Warrant	2.64
Expiration Date	Dec. 18, 2017
Exercised	0
Warrants Outstanding	22,500
Warrant 7
Class of Warrant or Right [Line Items]
Grant Date	Oct. 29, 2013
Warrants Issued	4,455,231
Exercise Price | $ / shares	$ 0.01
Weighted Average Exercise Price | $ / Warrant	0.01
Expiration Date	Oct. 29, 2018
Exercised	0
Warrants Outstanding	4,455,231
Warrant 8
Class of Warrant or Right [Line Items]
Grant Date	Oct. 29, 2013
Warrants Issued	12,868,585
Exercise Price | $ / shares	$ 4
Weighted Average Exercise Price | $ / Warrant	4
Expiration Date	Oct. 29, 2018
Exercised	0
Warrants Outstanding	12,868,585
Warrant 9
Class of Warrant or Right [Line Items]
Grant Date	Oct. 29, 2013
Warrants Issued	65,650
Exercise Price | $ / shares	$ 2.64
Weighted Average Exercise Price | $ / Warrant	2.64
Expiration Date	Oct. 29, 2018
Exercised	0
Warrants Outstanding	65,650
Total Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants Issued	28,924,681
Weighted Average Exercise Price | $ / Warrant	2.81
Exercised	0
Warrants Outstanding	28,924,681

Stock Option Plan - Additional

Stock Option Plan - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Oct. 07, 2013	Jan. 14, 2013	Apr. 25, 2011	Jun. 03, 2008
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of stock options granted under 2005 Plan (in years)			7 years 10 months 10 days
Fair value of options vested under 2005 Plan	$ 974,425	$ 955,740	$ 2,655,262	$ 1,916,729
Total unrecognized estimated compensation cost related to stock options	$ 5,647,085		$ 5,647,085
Total unrecognized estimated compensation cost related to stock options, recognition period			2 years 4 months 24 days
Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Available For Grant	3,905,808		3,905,808
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Term of stock options granted under 2005 Plan (in years)			10 years
Stock Options, Warrants Restricted Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Available For Grant	3,905,808		3,905,808
2005 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock reserved for issuance under 2005 Plan					11,155,295	945,276	875,000	373,831

Options Granted (Detail)

Options Granted (Detail) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Options granted	0	0	0	2,186,957

Assumptions Used in Estimating

Assumptions Used in Estimating Fair Value of Each Option Award Granted Using Black-Scholes Option-Pricing Model (Detail) - Jun. 30, 2014 - $ / shares	Total
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected Volatility	92.00%
Expected term	6 years
Dividend yield	0.00%
Forfeiture rate	0.00%
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.57%
Stock price	$ 2.23
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.58%
Stock price	$ 2.90

Summary of Status of Options Is

Summary of Status of Options Issued and Changes in Options Outstanding (Detail) - Jun. 30, 2015 - USD ($)	Total
Number of Shares
Balance at June 30, 2015	7,209,507
Exercisable at June 30, 2015	3,990,184
Shares available for grant under the 2005 Plan	3,905,808
Weighted-Average Exercise Price
Balance at June 30, 2015	$ 2.59
Exercisable at June 30, 2015	$ 2.73
Stock Option Plan
Number of Shares
Balance at December 31, 2014	7,339,118
Options Granted	0
Options Exercised	0
Options Cancelled	(129,611)
Balance at June 30, 2015	7,209,507
Options vested and expected to vest at June 30, 2015	7,209,507
Exercisable at June 30, 2015	3,990,184
Weighted-Average Exercise Price
Balance at December 31, 2014	$ 2.59
Options Granted	0
Options Exercised	0
Options Cancelled	2.75
Balance at June 30, 2015	2.59
Options vested and expected to vest at June 30, 2015	2.59
Exercisable at June 30, 2015	$ 2.73
Aggregate Intrinsic Value
Balance at December 31, 2014	$ 0
Options Granted	0
Options Exercised	0
Options Cancelled	0
Balance at June 30, 2015	0
Options vested and expected to vest at June 30, 2015	0
Exercisable at June 30, 2015	$ 0

Summary of Information about St

Summary of Information about Stock Options Outstanding (Detail) - Jun. 30, 2015 - $ / shares	Total
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Shares	7,209,507
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	7 years 10 months 10 days
Options Outstanding, Weighted-Average Exercise Price	$ 2.59
Options Exercisable, Shares	3,990,184
Options Exercisable, Weighted- Average Exercise Price	$ 2.73
Exercise Price 1
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price	$ 0.85
Options Outstanding, Shares	136,785
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	9 years 4 months 6 days
Options Outstanding, Weighted-Average Exercise Price	$ 0.85
Options Exercisable, Shares	26,597
Options Exercisable, Weighted- Average Exercise Price	$ 0.85
Exercise Price 2
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price	$ 1.30
Options Outstanding, Shares	100,000
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	9 years 3 months 7 days
Options Outstanding, Weighted-Average Exercise Price	$ 1.30
Options Exercisable, Shares	0
Options Exercisable, Weighted- Average Exercise Price	$ 1.30
Exercise Price 3
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price	$ 2.23
Options Outstanding, Shares	223,445
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	8 years 7 months 24 days
Options Outstanding, Weighted-Average Exercise Price	$ 2.23
Options Exercisable, Shares	83,792
Options Exercisable, Weighted- Average Exercise Price	$ 2.23
Exercise Price 4
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price	$ 2.40
Options Outstanding, Shares	5,188,107
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	7 years 8 months 8 days
Options Outstanding, Weighted-Average Exercise Price	$ 2.40
Options Exercisable, Shares	3,020,588
Options Exercisable, Weighted- Average Exercise Price	$ 2.40
Exercise Price 5
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price	$ 2.90
Options Outstanding, Shares	1,458,787
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	8 years 4 months 10 days
Options Outstanding, Weighted-Average Exercise Price	$ 2.90
Options Exercisable, Shares	756,824
Options Exercisable, Weighted- Average Exercise Price	$ 2.90
Exercise Price 6
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price	$ 8
Options Outstanding, Shares	65,000
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	5 years 25 days
Options Outstanding, Weighted-Average Exercise Price	$ 8
Options Exercisable, Shares	65,000
Options Exercisable, Weighted- Average Exercise Price	$ 8
Exercise Price 7
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price	$ 19.38
Options Outstanding, Shares	37,383
Options Outstanding, Weighted- Average Remaining Contractual Life (Years)	2 years 9 months 11 days
Options Outstanding, Weighted-Average Exercise Price	$ 19.38
Options Exercisable, Shares	37,383
Options Exercisable, Weighted- Average Exercise Price	$ 19.38

Stock-Based Compensation Costs

Stock-Based Compensation Costs (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation costs	$ 956,951	$ 1,252,973	$ 1,922,959	$ 2,418,029
Research and development
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation costs	284,947	300,259	554,750	547,586
General and administrative
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Stock-based compensation costs	$ 672,004	$ 952,714	$ 1,368,209	$ 1,870,443